Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD

Summary

This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.

Timeline

Start

2025-02-18

Primary completion

2026-09-30

Completion

2027-01-30

Drugs

Indications